70 results about "Venlafaxine Hydrochloride" patented technology

The present invention relates to an improved process for the preparation of phenethylamine derivatives or salts by hydrogenation of phenylacetonitriles in the presence of heterogeneous palladium on carbon catalyst.

This invention relates to an extended release tableted dosage formulation of the antidepressant venlafaxine hydrochloride or an optical form thereof having improved bioavailability.

The extended release osmo-microsealed formulation includes three controlled release systems associated in series. First, there is an inner solid particulate phase containing Venlafaxine Hydrochloride (Active), and one or more hydrophobic polymers, one or more diluents required to increase the bulk one or more osmogen (agents which can generate osmotic pressure across the hydrophobic coating) and one or more binder polymers essentially to provide strength/hardness to the particle. Second, there is an outer solid continuous phase including one or more hydrophilic polymers, that is further compressed into a tablet. Third, there is an optional functional coat surrounding the tablet. The process/method for forming the Osmo-microsealed extended release delivery system and the process for using such system for treating human ailment/depression are also provided.

The invention discloses a venlafaxine hydrochloride sustained-release tablet preparation which comprises venlafaxine hydrochloride, framework material, diluent, lubricant, adhesive and coating material. The experiments demonstrate that the venlafaxine hydrochloride sustained-release tablet achieves better sustained-release effect, can reduce the dosing frequency and is convenient for the patients to use. The invention also provides a preparation method thereof.

The invention discloses a venlafaxine hydrochloride spansule and a preparation method thereof. According to the existing method, aqueous dispersion is used for coating, and venlafaxine hydrochloride generates migration during the coating process due to high water solubility of venlafaxine hydrochloride, so that venlafaxine hydrochloride is possible to become a pore-forming agent to result in overquick release of venlafaxine hydrochloride if the thickness of a coating film is insufficient. The venlafaxine hydrochloride spansule disclosed by the invention is characterized in that the medicated micro-pill comprises a medicated pill core, an isolating layer coating the medicated pill core and a release control layer coating the isolating layer, wherein the medicated pill core is prepared from the following ingredients in percentage by weight: 30-60% of venlafaxine hydrochloride, 30-80% of filler, 1-20% of release skeleton material and 1-10% of adhesive. According to the invention, such technical problems as potential safety hazard to operators and high demands on equipment caused by utilizing organic solvents, namely dichloromethane and ethanol, for coating are completely solved.

The present invention discloses one kind of osmotic pump controlled release tablet of venlafaxine hydrochloride. The tablet consists of medicine core of venlafaxine hydrochloride and semipermeable film coating with small holes. The medicine core consists of venlafaxine hydrochloride in 75 weight portions, stuffing in 30-250 weight portions, osmotic pressure promoter in 1-50 weight portions, adhesive in 1-20 weight portions and lubricant in 0.1-20 weight portions. The semipermeable film coating consists of semipermeable film coating material in 5-15 weight portions and plasticizer in 1 weight portion. The tablet has excellent release controlling effect, high safety and good patient dependence. The present invention also discloses the preparation process of the osmotic pump controlled release tablet of venlafaxine hydrochloride.

A modified release tablet of venlafaxine hydrochloride is formed by a core containing a lipophilic matrix and venlafaxine hydrochloride and a water-insoluble, permeable coating thereover.

The invention relates to a venlafaxine hydrochloride film-controlled slow-release pellet capsule. A slow-release film of the venlafaxine hydrochloride film-controlled slow-release pellet utilizes Kollicoat SR30D as a film-formation material. A pellet core of the venlafaxine hydrochloride film-controlled slow-release pellet contains low-substituted hydroxyprepyl cellulose having high expansibility, and also contains a pharmaceutically-acceptable common excipient for the slow-release pellet, wherein preferably, the excipient comprises microcrystalline cellulose, and the pellet core comprises 10 to 40wt% of low-substituted hydroxyprepyl cellulose. The slow-release film comprises Kollicoat SR30D, triethyl citrate as a plasticizer and talcum powder as an antiplastering aid, wherein preferably, a ratio of Kollicoat SR30D to triethyl citrate to talcum powder is 30: 1: 4 and a film weight increasing ratio is in a range of 21 to 39%. The venlafaxine hydrochloride film-controlled slow-release pellet comprises the pellet core containing low-substituted hydroxyprepyl cellulose having high water expansibility and thus after absorbing water, the venlafaxine hydrochloride film-controlled slow-release pellet obviously expands so that the slow-release film is stretched; the thickness of the slow-release film is reduced; the water-permeable micropore size is increased; and permeability is improved and the permeability reduction caused by film aging is counteracted. Therefore, in middle and later stages, the venlafaxine hydrochloride film-controlled slow-release pellet release rate is basically constant; in the last stage, residues are less; and stable release performances can be kept in the period of validity.

The invention provides a venlafaxine hydrochloride controlled-release pellet and a preparation method thereof. The venlafaxine hydrochloride controlled-release pellet comprises a blank pellet core, a venlafaxine hydrochloride-containing layer and a controlled-release film, wherein the venlafaxine hydrochloride-containing layer comprises active components including venlafaxine hydrochloride and talcum powder which are in a weight ratio of 12:1-8:1, and the weight ratio of the venlafaxine hydrochloride to the blank pellet core is 4:10-8:10. The venlafaxine hydrochloride controlled-release pellet is prepared by adopting a fluidized bed bottom-spraying venlafaxine hydrochloride applying mode; by using 75 percent alcohol as a solvent, the viscosity of the venlafaxine hydrochloride in a water solution is remarkably lowered, the venlafaxine hydrochloride applying speed is increased; and the prepared venlafaxine hydrochloride containing pellet adopts a bottom-spraying coating process, thus the problem of static electricity generated because of the adoption of the pure organic solvent is overcome; the application process and the wrapping process can be continuously operated in the same device, thus the production efficiency is increased and the production cost is lowered; and no toxic organic solvent is adopted in the whole process, thus the venlafaxine hydrochloride controlled-release pellet is environmental-friendly and is good in stability, and almost no broken pellets or dust is produced.

This invention relates to a highly thermally stable novel anhydrous crystalline polymorphic form of venlafaxine hydrochloride, methods for the preparation thereof, and its use.

The invention relates to a venlafaxine hydrochloride slow-release capsule and a preparation method thereof. A drug-containing core of the slow-release capsule comprises venlafaxine hydrochloride, microcrystalline cellulose, gas phase silica, Tween-80, and hydroxypropyl methylcellulose; a slow-release coating comprises polyacrylic resin, talcum powder, polyethylene glycol and lauryl sodium sulfate. The invention realizes a pure water system for the capsule production by the addition of gas phase silica to change material flowing, and the selection of slow-release coating. The venlafaxine hydrochloride slow-release capsule prepared by the system is stable in drug release, has effective continuous release time of 24 hours, and is taken only once a day. The method is simple in process, mild in condition, free of any organic solvent, low in equipment requirements, and suitable for industrial production.

The invention relates to the field of medicines and in particular to a venlafaxine hydrochloride sustained-release capsule composition. The content of the venlafaxine hydrochloride sustained-release capsule composition comprises a sustained-release micropill composed of a medicine carrying micropill and a sustained-release layer; the medicine carrying micropill is composed of 58-66 parts by weight of venlafaxine hydrochloride, 75-85 parts by weight of filler and 8-12 parts by weight of an adhesive; the sustained-release layer is composed of 3.5-6 parts by weight of a sustained-release coating material and 18-27 parts by weight of a pore-foaming agent; the mass of the sustained-release layer is 14-17% of that of the medicine carrying layer. The invention also provides a preparation method of the venlafaxine hydrochloride sustained-release capsule composition. The medicine carrying micropill is manufactured by using a fluidized bed and the micropill is coated by the sustained-release layer to obtain the sustained-release micropill. The venlafaxine hydrochloride sustained-release capsule composition prepared by the method does not contain auxiliary materials such as an antisticking agent and a plasticizer. The manufacturing condition can be met by adjusting the process of the fluidized bed to obtain a drug which is close to an original drug in effect; the cost is lowered and the process difficulty is reduced.

The invention provides a slow-release composition containing antidepressant. The release speed of venlafaxine hydrochloride can be controlled by adding thinning agent and slow-release auxiliary materials with a certain proportion, so that composition form with the slow-release characteristic can be obtained.

The invention discloses a preparation method of a venlafaxine hydrochloride intermediate. The preparation method comprises the following steps of in a micro-reactor loaded with a raney nickel screen net catalyst, enabling a compound I and hydrogen to react at the temperature of 20 to 40 DEG C, so as to obtain a compound II; adding the compound II into sulfuric acid, and forming salt, so as to obtain a target product, namely 1-[2-amino-1-(4-methoxyphenyl)ethyl]cyclohexanol sulfate (compound III). The preparation method has the advantages that on the basis of the original micro-reactor, the raney nickel screen net catalyst is creatively clamped to the connecting part of a pipeline, so that the catalyzing effect is enhanced, and the catalyst can be recycled; the damage to a slurry pump of the micro-reactor and the blockage of a reaction pipeline due to mixing of the catalyst into material liquid are avoided.

Disclosed herein is an extended release pharmaceutical formulation suitable for once daily administration, comprising a highly water soluble core consisting essentially of about 30 to about 40% by weight of venlafaxine hydrochloride, about 50 to about 80% by weight of water soluble diluent and about 2 to about 10% of water soluble binder and a coating layer having an effective combination of rate controlling polymers comprising water-soluble polymer and water insoluble, water permeable polymer.

Extended release pharmaceutical composition of Venlafaxine hydrochloride comprising a pharmaceutically acceptable capsule containing minitablets. The minitablets comprise from about 20% to about 70% by weight effective amount of Venlafaxine hydrochloride, polyvinyl acetate, one or more pharmaceutically acceptable excipients. The minitablets have diameter from about 1 mm to 5 mm and are coated with a release controlling composition.